-
1
-
-
53549085157
-
New drugs for type 2 diabetes mellitus: what is their place in therapy?
-
COI: 1:CAS:528:DC%2BD1cXhsFCrsrvF, PID: 18840004
-
Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. 2008;68(15):2131–62.
-
(2008)
Drugs
, vol.68
, Issue.15
, pp. 2131-2162
-
-
Krentz, A.J.1
Patel, M.B.2
Bailey, C.J.3
-
2
-
-
83455244389
-
A review of gliptins in 2011
-
COI: 1:CAS:528:DC%2BC3MXhs1SktLfF, PID: 22149369
-
Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13(1):81–99.
-
(2012)
Expert Opin Pharmacother
, vol.13
, Issue.1
, pp. 81-99
-
-
Scheen, A.J.1
-
3
-
-
77950891085
-
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3cXksl2hsLk%3D, PID: 20388897
-
Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410–8.
-
(2010)
JAMA
, vol.303
, Issue.14
, pp. 1410-1418
-
-
Phung, O.J.1
Scholle, J.M.2
Talwar, M.3
Coleman, C.I.4
-
4
-
-
79961222810
-
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences
-
COI: 1:CAS:528:DC%2BC3MXht1Gmt77M, PID: 21812507
-
Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441–67.
-
(2011)
Drugs
, vol.71
, Issue.11
, pp. 1441-1467
-
-
Baetta, R.1
Corsini, A.2
-
5
-
-
79956326006
-
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
-
COI: 1:CAS:528:DC%2BC3MXoslajtbg%3D, PID: 21320267
-
Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13(7):594–603.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.7
, pp. 594-603
-
-
Esposito, K.1
Cozzolino, D.2
Bellastella, G.3
-
6
-
-
77954277563
-
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3cXpvVejt7g%3D, PID: 20616619
-
Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86(1):44–57.
-
(2010)
Pharmacology
, vol.86
, Issue.1
, pp. 44-57
-
-
Fakhoury, W.K.1
Lereun, C.2
Wright, D.3
-
7
-
-
77950880269
-
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
-
COI: 1:CAS:528:DC%2BC3cXptFygtbo%3D, PID: 19515542
-
Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–35.
-
(2010)
Nutr Metab Cardiovasc Dis
, vol.20
, Issue.4
, pp. 224-235
-
-
Monami, M.1
Iacomelli, I.2
Marchionni, N.3
Mannucci, E.4
-
8
-
-
77951758117
-
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3cXntVantL8%3D, PID: 20411998
-
Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010;30(5):463–84.
-
(2010)
Pharmacotherapy
, vol.30
, Issue.5
, pp. 463-484
-
-
Neumiller, J.J.1
Wood, L.2
Campbell, R.K.3
-
9
-
-
80051896369
-
Cytochrome P450-mediated cardiovascular drug interactions
-
COI: 1:CAS:528:DC%2BC3MXhtVWmsLrE, PID: 21810031
-
Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol. 2011;7(9):1065–82.
-
(2011)
Expert Opin Drug Metab Toxicol
, vol.7
, Issue.9
, pp. 1065-1082
-
-
Scheen, A.J.1
-
10
-
-
77958030736
-
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3cXhsVCrtbvK, PID: 20824678
-
Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26(7):540–9.
-
(2010)
Diabetes Metab Res Rev
, vol.26
, Issue.7
, pp. 540-549
-
-
Scheen, A.J.1
Charpentier, G.2
Ostgren, C.J.3
Hellqvist, A.4
Gause-Nilsson, I.5
-
11
-
-
68549101842
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
-
PID: 19622552
-
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
-
(2009)
BMJ
, vol.339
, pp. b2700
-
-
Liberati, A.1
Altman, D.G.2
Tetzlaff, J.3
-
12
-
-
84926039518
-
-
Proquest Dialog. (Accessed Nov 30, 2012).
-
Proquest Dialog. http://search.proquest.com/ (Accessed Nov 30, 2012).
-
-
-
-
13
-
-
84926039517
-
-
EBSCO. (Accessed Nov 30, 2012).
-
EBSCO. http://www.ebscohost.com/ (Accessed Nov 30, 2012).
-
-
-
-
14
-
-
84926039516
-
-
NHS Economic Evaluation Database (NHS EED). (Accessed Nov 30, 2012).
-
NHS Economic Evaluation Database (NHS EED). http://www.crd.york.ac.uk/crdweb/Homepage.asp (Accessed Nov 30, 2012).
-
-
-
-
15
-
-
84926039515
-
-
Health Economic Evaluations Database. (Accessed Nov 30, 2012).
-
Health Economic Evaluations Database. http://heed.onlinelibrary.wiley.com/heed/ohe/CnIsapi.dll?fld=X&alias=OHE&uni=58187&SetUserType=1&jump=Search&type=4&Browser=MSIE (Accessed Nov 30, 2012).
-
-
-
-
16
-
-
84926039514
-
-
American Diabetes Association (ADA) Conference Abstracts. (Accessed Nov 30, 2012).
-
American Diabetes Association (ADA) Conference Abstracts. http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=93229 (Accessed Nov 30, 2012).
-
-
-
-
17
-
-
84926039513
-
-
European Association for the Study of Diabetes (EASD). (Accessed Nov 30, 2012).
-
European Association for the Study of Diabetes (EASD). http://www.easd.org/ (Accessed Nov 30, 2012).
-
-
-
-
18
-
-
84926039512
-
-
International Diabetes Federation (IDF). (Accessed Nov 30, 2012).
-
International Diabetes Federation (IDF). http://www.idf.org/worlddiabetescongress/welcome (Accessed Nov 30, 2012).
-
-
-
-
19
-
-
84926039511
-
-
Canadian Diabetes Association (CDA). (Accessed Nov 30, 2012).
-
Canadian Diabetes Association (CDA). http://www.diabetes.ca/for-professionals/conference/montreal-2013/ (Accessed Nov 30, 2012).
-
-
-
-
20
-
-
84926039510
-
-
Health Technology Assessment International (HTAi). (Accessed Nov 30, 2012).
-
Health Technology Assessment International (HTAi). http://www.htai.org/ (Accessed Nov 30, 2012).
-
-
-
-
21
-
-
84926039509
-
-
International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (Accessed Nov 30, 2012).
-
International Society for Pharmacoeconomics and Outcomes Research (ISPOR). http://www.ispor.org/ (Accessed Nov 30, 2012).
-
-
-
-
22
-
-
84926039508
-
-
US National Institutes of Health (NIH). ClinicalTrials.gov. (Accessed Nov 30, 2012).
-
US National Institutes of Health (NIH). ClinicalTrials.gov. http://clinicaltrials.gov/ (Accessed Nov 30, 2012).
-
-
-
-
23
-
-
84926039507
-
-
International Network of Agencies for Health Technology Assessment (INAHTA). (Accessed Nov 30, 2012).
-
International Network of Agencies for Health Technology Assessment (INAHTA). http://www.inahta.org/HTA/ (Accessed Nov 30, 2012).
-
-
-
-
24
-
-
84926039506
-
-
National Institute for Health and Care Excellence (NICE). (Accessed Nov 30, 2012).
-
National Institute for Health and Care Excellence (NICE). http://www.nice.org.uk/ (Accessed Nov 30, 2012).
-
-
-
-
25
-
-
84926039505
-
-
National Institute for Health Research (NIHR) HTA. (Accessed Nov 30, 2012).
-
National Institute for Health Research (NIHR) HTA. http://www.hta.ac.uk/ (Accessed Nov 30, 2012).
-
-
-
-
26
-
-
84926039504
-
-
Canadian Agency for Drugs and Technologies in Health. (Accessed Nov 30, 2012).
-
Canadian Agency for Drugs and Technologies in Health. http://www.cadth.ca/ (Accessed Nov 30, 2012).
-
-
-
-
27
-
-
84926039503
-
-
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden (Version 4.0); 2011.
-
(2011)
Allgemeine Methoden (Version
, vol.4
, pp. 0
-
-
-
28
-
-
84926039502
-
-
l’Agence Nationale d’Accréditation et d’Evaluation en Santé (ANAES). Guide d’analyse de la litterature et gradation des recommendations. 2000.
-
l’Agence Nationale d’Accréditation et d’Evaluation en Santé (ANAES). Guide d’analyse de la litterature et gradation des recommendations. 2000.
-
-
-
-
29
-
-
84926039501
-
-
National Institute for Health and Care Excellence (NICE). Single technology appraisal (STA) template; 2012.
-
National Institute for Health and Care Excellence (NICE). Single technology appraisal (STA) template; 2012.
-
-
-
-
30
-
-
84926039500
-
-
CONSORT. (Accessed Nov, 2012).
-
CONSORT. http://www.consort-statement.org/home/ (Accessed Nov, 2012).
-
-
-
-
32
-
-
0036428867
-
Bayesian analysis of population PK/PD models: general concepts and software
-
COI: 1:CAS:528:DC%2BD38XntFGrt7w%3D, PID: 12449499
-
Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D. Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn. 2002;29(3):271–307.
-
(2002)
J Pharmacokinet Pharmacodyn
, vol.29
, Issue.3
, pp. 271-307
-
-
Lunn, D.J.1
Best, N.2
Thomas, A.3
Wakefield, J.4
Spiegelhalter, D.5
-
33
-
-
84855183915
-
Ades AE
-
Dias S, Welton N, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials; 2012.
-
(2012)
NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials
-
-
Dias, S.1
Welton, N.2
Sutton, A.J.3
Caldwell, D.M.4
Lu, G.5
-
34
-
-
84859016755
-
Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control
-
Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Ferreira JCA. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011;2(1):32–44.
-
(2011)
Diabetol Int
, vol.2
, Issue.1
, pp. 32-44
-
-
Tajima, N.1
Kadowaki, T.2
Odawara, M.3
Nishii, M.4
Taniguchi, T.5
Ferreira, J.C.A.6
-
35
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
-
PID: 20580422
-
Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–9.
-
(2010)
Lancet
, vol.376
, Issue.9739
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
-
36
-
-
77955262909
-
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study
-
COI: 1:CAS:528:DC%2BC3cXpslKhu7o%3D, PID: 20357372
-
Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509–15.
-
(2010)
Diabetes Care
, vol.33
, Issue.7
, pp. 1509-1515
-
-
Arnolds, S.1
Dellweg, S.2
Clair, J.3
-
37
-
-
83455264087
-
Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy
-
Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Diabetologia. 2011;54(Suppl 1):S108–9.
-
(2011)
Diabetologia
, vol.54
, pp. S108-S109
-
-
Barnett, A.H.1
Charbonnel, B.2
Li, J.3
Donovan, M.4
Fleming, D.5
-
38
-
-
84926042946
-
Efficacy and safety of linagliptin in elderly patients (>=70 years) with type 2 diabetes
-
Barnett AH, Huisman H, Jones R, Von Eynatten M, Patel S, Woerle H. Efficacy and safety of linagliptin in elderly patients (>=70 years) with type 2 diabetes. ADA. 2012;1017.
-
(2012)
ADA
, pp. 1017
-
-
Barnett, A.H.1
Huisman, H.2
Jones, R.3
Von Eynatten, M.4
Patel, S.5
Woerle, H.6
-
39
-
-
84856073305
-
Saxagliptin vs glipizide as add-on therapy to metformin for type 2 diabetes mellitus (T2DM): long-term safety and efficacy
-
Göke B, Gallwitz B, Eriksson J, Bokelundsingh S, Gause-Nilsson I. Saxagliptin vs glipizide as add-on therapy to metformin for type 2 diabetes mellitus (T2DM): long-term safety and efficacy. Diabetes. 2011;60(Suppl 1):A305.
-
(2011)
Diabetes
, vol.60
, pp. A305
-
-
Göke, B.1
Gallwitz, B.2
Eriksson, J.3
Bokelundsingh, S.4
Gause-Nilsson, I.5
-
40
-
-
84878420980
-
Addition of sitagliptin, an oral, highly-selective dipeptidyl peptidase-4 inhibitor, improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on insulin monotherapy
-
Kadowaki T, Tajima N, Odawara M, et al. Addition of sitagliptin, an oral, highly-selective dipeptidyl peptidase-4 inhibitor, improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetes. 2011;60(Suppl 1):A279–80.
-
(2011)
Diabetes
, vol.60
, pp. A279-A280
-
-
Kadowaki, T.1
Tajima, N.2
Odawara, M.3
-
41
-
-
84863791439
-
The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients
-
COI: 1:CAS:528:DC%2BC38XpvVOgt78%3D, PID: 22512265
-
Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14(7):561–7.
-
(2012)
Diabetes Technol Ther
, vol.14
, Issue.7
, pp. 561-567
-
-
Koren, S.1
Shemesh-Bar, L.2
Tirosh, A.3
-
42
-
-
84867142621
-
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
-
COI: 1:CAS:528:DC%2BC38XhsVCgur7I, PID: 22690943
-
Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14(11):1032–9.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.11
, pp. 1032-1039
-
-
Kothny, W.1
Shao, Q.2
Groop, P.H.3
Lukashevich, V.4
-
43
-
-
84925986896
-
Sitagliptin added to previously taken anti-diabetic agents on insulin-resistance and lipid profile: a two years study evaluation
-
Ragonesi PD, Maffioli P, Cicero AFG, et al. Sitagliptin added to previously taken anti-diabetic agents on insulin-resistance and lipid profile: a two years study evaluation. Diabetologia. 2012;55(Suppl 1):S342–3.
-
(2012)
Diabetologia
, vol.55
, pp. S342-S343
-
-
Ragonesi, P.D.1
Maffioli, P.2
Cicero, A.F.G.3
-
44
-
-
84926003076
-
Efficacy and safety of gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
-
Rhee EJ, Min KW, Jang HC, et al. Efficacy and safety of gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetologia. 2012;55(Suppl 1):S352.
-
(2012)
Diabetologia
, vol.55
, pp. S352
-
-
Rhee, E.J.1
Min, K.W.2
Jang, H.C.3
-
45
-
-
84920066045
-
Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes
-
Rosenstock J, Gross JL, Salinas CAA, et al. Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes. Diabetes. 2011;60(Suppl 1):A289–98.
-
(2011)
Diabetes
, vol.60
, pp. A289-A298
-
-
Rosenstock, J.1
Gross, J.L.2
Salinas, C.A.A.3
-
46
-
-
84925985521
-
Efficacy and safety of gemigliptin in patients with type 2 diabetes
-
Yang SJ, Min KW, Park JY, et al. Efficacy and safety of gemigliptin in patients with type 2 diabetes. Diabetologia. 2012;55(Suppl 1):S351–2.
-
(2012)
Diabetologia
, vol.55
, pp. S351-S352
-
-
Yang, S.J.1
Min, K.W.2
Park, J.Y.3
-
47
-
-
84862271963
-
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
-
COI: 1:CAS:528:DC%2BC38XosVaktbk%3D, PID: 22683131
-
Aschner P, Chan J, Owens DR, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262–9.
-
(2012)
Lancet
, vol.379
, Issue.9833
, pp. 2262-2269
-
-
Aschner, P.1
Chan, J.2
Owens, D.R.3
-
48
-
-
70349761649
-
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial—a primary care, type 2 diabetes study
-
COI: 1:CAS:528:DC%2BD1MXht12hu7jE, PID: 19614942
-
Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial—a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11(10):978–86.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.10
, pp. 978-986
-
-
Blonde, L.1
Dagogo-Jack, S.2
Banerji, M.A.3
-
49
-
-
84881566089
-
Efficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapy
-
Kim NH, Sung YA, Ahn CW, et al. Efficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapy. Diabetes. 2012;61(Suppl 1):A297.
-
(2012)
Diabetes
, vol.61
, pp. A297
-
-
Kim, N.H.1
Sung, Y.A.2
Ahn, C.W.3
-
50
-
-
77955024875
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. (vol 375, pg 1447, 2010)
-
Pratley RE, Nauck M, Bailey T. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. (vol 375, pg 1447, 2010). Lancet (North American Edition). 2010;376(9737):234.
-
(2010)
Lancet (North American Edition)
, vol.376
, Issue.9737
, pp. 234
-
-
Pratley, R.E.1
Nauck, M.2
Bailey, T.3
-
51
-
-
84865996053
-
Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study
-
COI: 1:CAS:528:DC%2BC38XhtlSmtLzI, PID: 22583697
-
Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14(10):927–36.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.10
, pp. 927-936
-
-
Seino, Y.1
Miyata, Y.2
Hiroi, S.3
Hirayama, M.4
Kaku, K.5
-
52
-
-
79955015666
-
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
-
PID: 21342412
-
Pfützner A, Paz-Pacheco E, Allen E, Frederich R, Chen R. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13(6):567–76.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.6
, pp. 567-576
-
-
Pfützner, A.1
Paz-Pacheco, E.2
Allen, E.3
Frederich, R.4
Chen, R.5
-
53
-
-
84867400778
-
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, b-cell function and insulin resistance in type 2 diabetic patients
-
COI: 1:CAS:528:DC%2BC38XosFWjur0%3D, PID: 22682949
-
Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, b-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98(1):51–60.
-
(2012)
Diabetes Res Clin Pract
, vol.98
, Issue.1
, pp. 51-60
-
-
Derosa, G.1
Carbone, A.2
Franzetti, I.3
-
54
-
-
80051872773
-
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes
-
PID: 21849007
-
Pérez-Monteverde A, Seck T, Xu L, et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. Int J Clin Pract. 2011;65(9):930–8.
-
(2011)
Int J Clin Pract
, vol.65
, Issue.9
, pp. 930-938
-
-
Pérez-Monteverde, A.1
Seck, T.2
Xu, L.3
-
55
-
-
84859444408
-
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC38XotVSms74%3D, PID: 22059736
-
Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(5):409–18.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.5
, pp. 409-418
-
-
Wainstein, J.1
Katz, L.2
Engel, S.S.3
-
56
-
-
65549123794
-
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
-
COI: 1:CAS:528:DC%2BD1MXnslKrtbo%3D, PID: 19515181
-
Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–22.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.6
, pp. 611-622
-
-
Jadzinsky, M.1
Pfützner, A.2
Paz-Pacheco, E.3
Xu, Z.4
Allen, E.5
Chen, R.6
-
57
-
-
78751562877
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of b-cell function in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3MXjt1WqtLo%3D, PID: 21235696
-
Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of b-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65(2):154–64.
-
(2011)
Int J Clin Pract
, vol.65
, Issue.2
, pp. 154-164
-
-
Yoon, K.H.1
Shockey, G.R.2
Teng, R.3
-
58
-
-
65449135133
-
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BD1MXmtVOks7c%3D, PID: 19320662
-
Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506–15.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.5
, pp. 506-515
-
-
Bosi, E.1
Dotta, F.2
Jia, Y.3
Goodman, M.4
-
59
-
-
84861982613
-
Vildagliptin added to metformin on b-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients
-
COI: 1:CAS:528:DC%2BC38Xot1Oks7g%3D, PID: 22512264
-
Derosa G, Ragonesi PD, Carbone A, et al. Vildagliptin added to metformin on b-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther. 2012;14(6):475–84.
-
(2012)
Diabetes Technol Ther
, vol.14
, Issue.6
, pp. 475-484
-
-
Derosa, G.1
Ragonesi, P.D.2
Carbone, A.3
-
60
-
-
67949105103
-
Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
-
COI: 1:CAS:528:DC%2BD1MXnslGmsL0%3D, PID: 19221978
-
Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009;41(5):368–73.
-
(2009)
Horm Metab Res
, vol.41
, Issue.5
, pp. 368-373
-
-
Goodman, M.1
Thurston, H.2
Penman, J.3
-
61
-
-
84864373418
-
Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study
-
COI: 1:CAS:528:DC%2BC38XhtFOmsLbF, PID: 22443183
-
Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012;14(9):795–802.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.9
, pp. 795-802
-
-
Hong, E.S.1
Khang, A.R.2
Yoon, J.W.3
-
62
-
-
77955428835
-
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3cXpvFWlsr8%3D, PID: 20537746
-
Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;89(3):216–23.
-
(2010)
Diabetes Res Clin Pract
, vol.89
, Issue.3
, pp. 216-223
-
-
Kikuchi, M.1
Haneda, M.2
Koya, D.3
-
63
-
-
67649933635
-
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
-
COI: 1:CAS:528:DC%2BD1MXpvV2jsLk%3D, PID: 19476473
-
Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804–12.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.8
, pp. 804-812
-
-
Schweizer, A.1
Dejager, S.2
Bosi, E.3
-
64
-
-
37349054435
-
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study
-
COI: 1:CAS:528:DC%2BD1cXislCrsrY%3D, PID: 18034842
-
Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10(1):82–90.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.1
, pp. 82-90
-
-
Bolli, G.1
Dotta, F.2
Rochotte, E.3
Cohen, S.E.4
-
65
-
-
84860711211
-
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC38XntV2isLo%3D, PID: 22419732
-
DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1615–22.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, Issue.5
, pp. 1615-1622
-
-
DeFronzo, R.A.1
Burant, C.F.2
Fleck, P.3
Wilson, C.4
Mekki, Q.5
Pratley, R.E.6
-
66
-
-
58149171060
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study
-
COI: 1:CAS:528:DC%2BD1MXltFKlsg%3D%3D, PID: 18809631
-
DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–7.
-
(2008)
Diabetes Care
, vol.31
, Issue.12
, pp. 2315-2317
-
-
DeFronzo, R.A.1
Fleck, P.R.2
Wilson, C.A.3
Mekki, Q.4
-
67
-
-
33847687205
-
Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
-
COI: 1:CAS:528:DC%2BD2sXltVamt7w%3D, PID: 17373638
-
Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39(3):218–23.
-
(2007)
Horm Metab Res
, vol.39
, Issue.3
, pp. 218-223
-
-
Dejager, S.1
Razac, S.2
Foley, J.E.3
Schweizer, A.4
-
68
-
-
84859463659
-
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
-
COI: 1:CAS:528:DC%2BC38Xjs1Sjsrw%3D, PID: 22237690
-
Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915–25.
-
(2012)
Diabetologia
, vol.55
, Issue.4
, pp. 915-925
-
-
Eliasson, B.1
Möller-Goede, D.2
Eeg-Olofsson, K.3
-
69
-
-
71849095372
-
Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3cXntFymsg%3D%3D, PID: 19705345
-
Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res. 2009;41(12):905–9.
-
(2009)
Horm Metab Res
, vol.41
, Issue.12
, pp. 905-909
-
-
Foley, J.E.1
Sreenan, S.2
-
70
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXkvFKju7s%3D, PID: 17387446
-
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148–55.
-
(2007)
Diabetologia
, vol.50
, Issue.6
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
Baron, M.A.4
Chang, I.5
Dejager, S.6
-
71
-
-
33846828660
-
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
-
COI: 1:CAS:528:DC%2BD2sXjs1Srt7c%3D, PID: 17300592
-
Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9(2):166–74.
-
(2007)
Diabetes Obes Metab
, vol.9
, Issue.2
, pp. 166-174
-
-
Garber, A.J.1
Schweizer, A.2
Baron, M.A.3
Rochotte, E.4
Dejager, S.5
-
72
-
-
54249106294
-
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
-
COI: 1:CAS:528:DC%2BD1cXhsVeqsLfI, PID: 18284434
-
Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047–56.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.11
, pp. 1047-1056
-
-
Garber, A.J.1
Foley, J.E.2
Banerji, M.A.3
-
73
-
-
80052551137
-
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC3MXhtlCnsb3F, PID: 21733061
-
Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):947–54.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.10
, pp. 947-954
-
-
Lukashevich, V.1
Schweizer, A.2
Shao, Q.3
Groop, P.H.4
Kothny, W.5
-
74
-
-
57649225147
-
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
-
COI: 1:CAS:528:DC%2BC3cXktFGnsbw%3D, PID: 19125992
-
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46–55.
-
(2009)
Int J Clin Pract
, vol.63
, Issue.1
, pp. 46-55
-
-
Nauck, M.A.1
Ellis, G.C.2
Fleck, P.R.3
Wilson, C.A.4
Mekki, Q.5
-
75
-
-
33846905487
-
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXhvVCktrc%3D, PID: 17223217
-
Pi-sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(1):132–8.
-
(2007)
Diabetes Res Clin Pract
, vol.76
, Issue.1
, pp. 132-138
-
-
Pi-sunyer, F.X.1
Schweizer, A.2
Mills, D.3
Dejager, S.4
-
76
-
-
33846827085
-
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXjs1SrtL4%3D, PID: 17300593
-
Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175–85.
-
(2007)
Diabetes Obes Metab
, vol.9
, Issue.2
, pp. 175-185
-
-
Rosenstock, J.1
Kim, S.W.2
Baron, M.A.3
-
77
-
-
79951699944
-
Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3cXhs1SisrzP, PID: 20724648
-
Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406–8.
-
(2010)
Diabetes Care
, vol.33
, Issue.11
, pp. 2406-2408
-
-
Rosenstock, J.1
Inzucchi, S.E.2
Seufert, J.3
Fleck, P.R.4
Wilson, C.A.5
Mekki, Q.6
-
78
-
-
84859013614
-
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study
-
COI: 1:CAS:528:DC%2BC38Xjt1ajurw%3D, PID: 22210563
-
Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–8.
-
(2012)
Diabetes Care
, vol.35
, Issue.2
, pp. 252-258
-
-
Russell-Jones, D.1
Cuddihy, R.M.2
Hanefeld, M.3
-
79
-
-
84926039498
-
-
World Health Organisation (WHO). The challenge of obesity in the WHO European Region and the strategies for response; 2014.
-
World Health Organisation (WHO). The challenge of obesity in the WHO European Region and the strategies for response; 2014.
-
-
-
-
80
-
-
79954508355
-
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC3MXksleqs7g%3D, PID: 21428727
-
Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049–58.
-
(2011)
Curr Med Res Opin
, vol.27
, Issue.5
, pp. 1049-1058
-
-
Barzilai, N.1
Guo, H.2
Mahoney, E.M.3
-
81
-
-
84926069356
-
Similar glucose control over 52 weeks with alogliptin vs glipizide in older, mildly hyperglycaemic patients with type 2 diabetes
-
Fleck P, Wilson C, Rosenstock J. Similar glucose control over 52 weeks with alogliptin vs glipizide in older, mildly hyperglycaemic patients with type 2 diabetes. Diabetologia. 2012;55(Suppl 1):S347.
-
(2012)
Diabetologia
, vol.55
, pp. S347
-
-
Fleck, P.1
Wilson, C.2
Rosenstock, J.3
-
82
-
-
77955020170
-
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients
-
COI: 1:CAS:528:DC%2BC3cXhtFygsr%2FP, PID: 20560108
-
Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010;42(9):663–9.
-
(2010)
Horm Metab Res
, vol.42
, Issue.9
, pp. 663-669
-
-
Derosa, G.1
Maffioli, P.2
Ferrari, I.3
-
83
-
-
77952316298
-
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
-
COI: 1:CAS:528:DC%2BC3cXmsVehsbY%3D, PID: 20015525
-
Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. 2010;59(6):887–95.
-
(2010)
Metabolism
, vol.59
, Issue.6
, pp. 887-895
-
-
Derosa, G.1
Maffioli, P.2
Salvadeo, S.A.3
-
84
-
-
80051713709
-
Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study
-
COI: 1:CAS:528:DC%2BC3MXhtVWmsLzO, PID: 21806314
-
Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781–92.
-
(2011)
Curr Med Res Opin
, vol.27
, Issue.9
, pp. 1781-1792
-
-
Seino, Y.1
Fujita, T.2
Hiroi, S.3
Hirayama, M.4
Kaku, K.5
-
85
-
-
84859040910
-
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone
-
Srivastava S, Saxena GN, Keshwani P, Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. J Assoc Phys India. 2012;60:27–30.
-
(2012)
J Assoc Phys India
, vol.60
, pp. 27-30
-
-
Srivastava, S.1
Saxena, G.N.2
Keshwani, P.3
Gupta, R.4
-
86
-
-
77954380946
-
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3cXltVahtr8%3D, PID: 20380653
-
Aaboe K, Knop FK, Visbøll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2010;12(4):323–33.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.4
, pp. 323-333
-
-
Aaboe, K.1
Knop, F.K.2
Visbøll, T.3
-
87
-
-
65649139912
-
Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BD1MXkvFGrsrg%3D, PID: 19253204
-
Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson-Levonas AO, Amatruda JM. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res. 2009;41(3):232–7.
-
(2009)
Horm Metab Res
, vol.41
, Issue.3
, pp. 232-237
-
-
Nonaka, K.1
Tsubouchi, H.2
Okuyama, K.3
Fukao, Y.4
Johnson-Levonas, A.O.5
Amatruda, J.M.6
-
88
-
-
34147093268
-
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
-
COI: 1:CAS:528:DC%2BD2sXkvVOgu78%3D, PID: 17277036
-
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890–5.
-
(2007)
Diabetes Care
, vol.30
, Issue.4
, pp. 890-895
-
-
Bosi, E.1
Camisasca, R.P.2
Collober, C.3
Rochotte, E.4
Garber, A.J.5
-
89
-
-
69549135336
-
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
-
COI: 1:CAS:528:DC%2BD1MXht1agtrzF, PID: 19478198
-
DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–55.
-
(2009)
Diabetes Care
, vol.32
, Issue.9
, pp. 1649-1655
-
-
DeFronzo, R.A.1
Hissa, M.N.2
Garber, A.J.3
-
90
-
-
39749184723
-
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1cXktlahsrY%3D, PID: 18194595
-
Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537–50.
-
(2008)
Curr Med Res Opin
, vol.24
, Issue.2
, pp. 537-550
-
-
Raz, I.1
Chen, Y.2
Wu, M.3
-
91
-
-
80053422772
-
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
-
COI: 1:CAS:528:DC%2BC3MXhsVOjsrbF, PID: 21682833
-
Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028–35.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.11
, pp. 1028-1035
-
-
Kaku, K.1
Itayasu, T.2
Hiroi, S.3
Hirayama, M.4
Seino, Y.5
-
92
-
-
58149335320
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
-
COI: 1:CAS:528:DC%2BD1MXivVWjtLc%3D, PID: 19125778
-
Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167–76.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.2
, pp. 167-176
-
-
Pratley, R.E.1
Kipnes, M.S.2
Fleck, P.R.3
Wilson, C.4
Mekki, Q.5
-
93
-
-
78851472527
-
Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
-
PID: 21205122
-
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258–67.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.3
, pp. 258-267
-
-
Del Prato, S.1
Barnett, A.H.2
Huisman, H.3
Neubacher, D.4
Woerle, H.J.5
Dugi, K.A.6
-
94
-
-
79953044464
-
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3MXktVemtA%3D%3D, PID: 21059094
-
Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010;27(12):1409–19.
-
(2010)
Diabet Med
, vol.27
, Issue.12
, pp. 1409-1419
-
-
Forst, T.1
Uhlig-Laske, B.2
Ring, A.3
-
95
-
-
84864757433
-
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
-
COI: 1:CAS:528:DC%2BC38XpvFGis7o%3D
-
Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet (North American Edition). 2012;380(9840):475–83.
-
(2012)
Lancet (North American Edition)
, vol.380
, Issue.9840
, pp. 475-483
-
-
Gallwitz, B.1
Rosenstock, J.2
Rauch, T.3
-
96
-
-
79953174825
-
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
-
COI: 1:CAS:528:DC%2BC3MXoslaju74%3D, PID: 21410628
-
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(7):653–61.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.7
, pp. 653-661
-
-
Gomis, R.1
Espadero, R.M.2
Jones, R.3
Woerle, H.J.4
Dugi, K.A.5
-
97
-
-
84862813117
-
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
-
COI: 1:CAS:528:DC%2BC38XhtVSgsrvN, PID: 22356132
-
Haak T, Meinicke T, Jones R, Weber S, Von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14(6):565–74.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.6
, pp. 565-574
-
-
Haak, T.1
Meinicke, T.2
Jones, R.3
Weber, S.4
Von Eynatten, M.5
Woerle, H.J.6
-
98
-
-
84858003503
-
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
-
COI: 1:CAS:528:DC%2BC38XmtVKjsLg%3D, PID: 22145698
-
Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14(4):348–57.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.4
, pp. 348-357
-
-
Kawamori, R.1
Inagaki, N.2
Araki, E.3
-
99
-
-
84866183265
-
Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC38XhtlOju7fF, PID: 22939034
-
Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012;34(9):1909–19.
-
(2012)
Clin Ther
, vol.34
, Issue.9
, pp. 1909-1919
-
-
Lewin, A.J.1
Arvay, L.2
Liu, D.3
Patel, S.4
von Eynatten, M.5
Woerle, H.J.6
-
100
-
-
80053072352
-
Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
-
COI: 1:CAS:528:DC%2BC3MXhsFWhsrzO, PID: 21781152
-
Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28(11):1352–61.
-
(2011)
Diabet Med
, vol.28
, Issue.11
, pp. 1352-1361
-
-
Owens, D.R.1
Swallow, R.2
Dugi, K.A.3
Woerle, H.J.4
-
101
-
-
84866651423
-
Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC38Xhtl2ltLfK, PID: 22816729
-
Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012;28(9):1465–74.
-
(2012)
Curr Med Res Opin
, vol.28
, Issue.9
, pp. 1465-1474
-
-
Ross, S.A.1
Rafeiro, E.2
Meinicke, T.3
Toorawa, R.4
Weber-Born, S.5
Woerle, H.J.6
-
102
-
-
78649691630
-
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
-
COI: 1:CAS:528:DC%2BC3MXlslamug%3D%3D, PID: 21114605
-
Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.1
, pp. 65-74
-
-
Taskinen, M.R.1
Rosenstock, J.2
Tamminen, I.3
-
103
-
-
68949212458
-
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
-
COI: 1:CAS:528:DC%2BC3cXksVeqsrg%3D, PID: 19614786
-
Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–406.
-
(2009)
Int J Clin Pract
, vol.63
, Issue.9
, pp. 1395-1406
-
-
Chacra, A.R.1
Tan, G.H.2
Apanovitch, A.3
Ravichandran, S.4
List, J.5
Chen, R.6
-
104
-
-
84858006384
-
Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage
-
COI: 1:CAS:528:DC%2BC38XmtVKjsb4%3D, PID: 22192246
-
Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012;14(4):365–71.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.4
, pp. 365-371
-
-
Fonseca, V.1
Zhu, T.2
Karyekar, C.3
Hirshberg, B.4
-
105
-
-
78349292168
-
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
-
PID: 20846286
-
Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–31.
-
(2010)
Int J Clin Pract
, vol.64
, Issue.12
, pp. 1619-1631
-
-
Göke, B.1
Gallwitz, B.2
Eriksson, J.3
Hellqvist, A.4
Gause-Nilsson, I.5
-
106
-
-
84863230449
-
Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
-
COI: 1:CAS:528:DC%2BC38XjsVSqsr0%3D, PID: 22081481
-
Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28(3):268–75.
-
(2012)
Diabetes Metab Res Rev
, vol.28
, Issue.3
, pp. 268-275
-
-
Pan, C.Y.1
Yang, W.2
Tou, C.3
Gause-Nilsson, I.4
Zhao, J.5
-
107
-
-
70349333861
-
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1MXhtFCgsLfK, PID: 19650754
-
Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–11.
-
(2009)
Curr Med Res Opin
, vol.25
, Issue.10
, pp. 2401-2411
-
-
Rosenstock, J.1
Aguilar-Salinas, C.2
Klein, E.3
Nepal, S.4
List, J.5
Chen, R.6
-
108
-
-
81255160603
-
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial
-
COI: 1:CAS:528:DC%2BC3MXhsV2ht73N, PID: 21871686
-
Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011;94(2):217–24.
-
(2011)
Diabetes Res Clin Pract
, vol.94
, Issue.2
, pp. 217-224
-
-
Yang, W.1
Pan, C.Y.2
Tou, C.3
Zhao, J.4
Gause-Nilsson, I.5
-
109
-
-
78650656671
-
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
-
COI: 1:CAS:528:DC%2BC3MXhvVGjtL4%3D, PID: 21199268
-
Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–8.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.2
, pp. 160-168
-
-
Arechavaleta, R.1
Seck, T.2
Chen, Y.3
-
110
-
-
33845472504
-
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXhtVGhtA%3D%3D, PID: 17130196
-
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–7.
-
(2006)
Diabetes Care
, vol.29
, Issue.12
, pp. 2632-2637
-
-
Aschner, P.1
Kipnes, M.S.2
Lunceford, J.K.3
Sanchez, M.4
Mickel, C.5
Williams-Herman, D.E.6
-
111
-
-
33845476757
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
-
COI: 1:CAS:528:DC%2BD2sXhtVGhtQ%3D%3D, PID: 17130197
-
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–43.
-
(2006)
Diabetes Care
, vol.29
, Issue.12
, pp. 2638-2643
-
-
Charbonnel, B.1
Karasik, A.2
Liu, J.3
Wu, M.4
Meininger, G.5
-
112
-
-
34547660561
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXpsleksr8%3D, PID: 17485570
-
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–87.
-
(2007)
Diabetes Care
, vol.30
, Issue.8
, pp. 1979-1987
-
-
Goldstein, B.J.1
Feinglos, M.N.2
Lunceford, J.K.3
Johnson, J.4
Williams-Herman, D.E.5
-
113
-
-
65449135058
-
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
-
COI: 1:CAS:528:DC%2BD1MXltVWmsbw%3D, PID: 19232032
-
Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569–83.
-
(2009)
Curr Med Res Opin
, vol.25
, Issue.3
, pp. 569-583
-
-
Williams-Herman, D.1
Johnson, J.2
Teng, R.3
-
114
-
-
34347219401
-
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXosF2isrg%3D, PID: 17559733
-
Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23(6):1329–39.
-
(2007)
Curr Med Res Opin
, vol.23
, Issue.6
, pp. 1329-1339
-
-
Hanefeld, M.1
Herman, G.A.2
Wu, M.3
Mickel, C.4
Sanchez, M.5
Stein, P.P.6
-
115
-
-
34547863123
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
-
COI: 1:CAS:528:DC%2BD2sXhtFGgt7vO, PID: 17593236
-
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–45.
-
(2007)
Diabetes Obes Metab
, vol.9
, Issue.5
, pp. 733-745
-
-
Hermansen, K.1
Kipnes, M.2
Luo, E.3
Fanurik, D.4
Khatami, H.5
Stein, P.6
-
116
-
-
77954197187
-
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
-
COI: 1:CAS:528:DC%2BC3cXptlWrtLs%3D, PID: 20590736
-
Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab. 2010;12(7):613–22.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.7
, pp. 613-622
-
-
Iwamoto, Y.1
Tajima, N.2
Kadowaki, T.3
-
117
-
-
33846817233
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
-
COI: 1:CAS:528:DC%2BD2sXjs1SrtLw%3D, PID: 17300595
-
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205.
-
(2007)
Diabetes Obes Metab
, vol.9
, Issue.2
, pp. 194-205
-
-
Nauck, M.A.1
Meininger, G.2
Sheng, D.3
Terranella, L.4
Stein, P.P.5
-
118
-
-
38349126264
-
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1cXhsVKitro%3D, PID: 17933414
-
Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291–8.
-
(2008)
Diabetes Res Clin Pract
, vol.79
, Issue.2
, pp. 291-298
-
-
Nonaka, K.1
Kakikawa, T.2
Sato, A.3
-
119
-
-
79956315355
-
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3MXoslajurk%3D, PID: 21410627
-
Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–52.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.7
, pp. 644-652
-
-
Reasner, C.1
Olansky, L.2
Seck, T.L.3
-
120
-
-
43449096512
-
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1cXht1Klur7O, PID: 18201203
-
Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959–69.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.10
, pp. 959-969
-
-
Scott, R.1
Loeys, T.2
Davies, M.J.3
Engel, S.S.4
-
121
-
-
58149330590
-
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
-
COI: 1:CAS:528:DC%2BD1MXivVWjtLk%3D, PID: 19125777
-
Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–66.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.2
, pp. 157-166
-
-
Ferrannini, E.1
Fonseca, V.2
Zinman, B.3
-
122
-
-
77949356196
-
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
-
COI: 1:CAS:528:DC%2BC3cXksl2ntL4%3D, PID: 20536495
-
Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(3):318–26.
-
(2010)
Diabet Med
, vol.27
, Issue.3
, pp. 318-326
-
-
Filozof, C.1
Gautier, J.F.2
-
123
-
-
84926013188
-
Vildagliptin added to once or twice daily insulin regimens improves glycaemic control without increasing risk of hypoglycaemia and weight gain in patients with type 2 diabetes
-
Kothny W, Kozlovski P, Foley J, Shao Q, Lukashevich V. Vildagliptin added to once or twice daily insulin regimens improves glycaemic control without increasing risk of hypoglycaemia and weight gain in patients with type 2 diabetes. Diabetologia. 2012;55(Suppl 1):S354.
-
(2012)
Diabetologia
, vol.55
, pp. S354
-
-
Kothny, W.1
Kozlovski, P.2
Foley, J.3
Shao, Q.4
Lukashevich, V.5
-
124
-
-
84926028996
-
Vildagliptin efficacy and safety in patients with type 2 diabetes inadequately controlled on dual metformin plus sulfonylurea therapy
-
Lukashevich V, Wang M, Del Prato S, Araga M, Kothny W. Vildagliptin efficacy and safety in patients with type 2 diabetes inadequately controlled on dual metformin plus sulfonylurea therapy. Diabetologia. 2012;55(Suppl 1):S353.
-
(2012)
Diabetologia
, vol.55
, pp. S353
-
-
Lukashevich, V.1
Wang, M.2
Del Prato, S.3
Araga, M.4
Kothny, W.5
-
125
-
-
77955048324
-
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
-
COI: 1:CAS:528:DC%2BC3cXhtFGntbnP, PID: 20649630
-
Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780–9.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.9
, pp. 780-789
-
-
Matthews, D.R.1
Dejager, S.2
Ahren, B.3
-
126
-
-
84863312882
-
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC38XhtlGhtL%2FP, PID: 22369287
-
Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(8):737–44.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.8
, pp. 737-744
-
-
Pan, C.1
Xing, X.2
Han, P.3
-
127
-
-
34548118796
-
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2sXhtFejsb3L, PID: 17509069
-
Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24(9):955–61.
-
(2007)
Diabet Med
, vol.24
, Issue.9
, pp. 955-961
-
-
Schweizer, A.1
Couturier, A.2
Foley, J.E.3
Dejager, S.4
|